Last checked at 10 Jun 2019 14:34
PDMR Dealings / Market Share sale
Oxford, UK - 10 June 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 June 2019, that Dr. Jason Slingsby, Chief Business Officer of the Group, exercised 12,014 options at 274.7p each and sold all of the resulting shares at 760p. Following this transaction he holds 91,822 options and no shares in the Company.
The issued share capital of the Group is 76,738,168 ordinary 50p shares.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Jason Slingsby | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Business Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford BioMedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Exercise of options | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s) |
| ||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
12,014
£2.747
£33,002.46 | ||||
f) | Date of the transaction | 2019-06-07 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Jason Slingsby | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Business Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford BioMedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Disposal | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s) |
| ||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
12,014
£7.60
£91,306.40 | ||||
f) | Date of the transaction | 2019-06-07 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Stuart Paynter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com